WO2024040593A1 - Médicament anti-pneumonie, son procédé de préparation et son utilisation - Google Patents
Médicament anti-pneumonie, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2024040593A1 WO2024040593A1 PCT/CN2022/115234 CN2022115234W WO2024040593A1 WO 2024040593 A1 WO2024040593 A1 WO 2024040593A1 CN 2022115234 W CN2022115234 W CN 2022115234W WO 2024040593 A1 WO2024040593 A1 WO 2024040593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- protein
- pneumonia
- cyclophilin
- binding
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 229940079593 drug Drugs 0.000 title claims abstract description 31
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 28
- 108010072220 Cyclophilin A Proteins 0.000 claims abstract description 20
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 20
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims abstract description 20
- 239000003580 lung surfactant Substances 0.000 claims abstract description 17
- 239000002245 particle Substances 0.000 claims abstract description 16
- 230000000903 blocking effect Effects 0.000 claims abstract description 8
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 36
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 28
- 235000012000 cholesterol Nutrition 0.000 claims description 18
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 16
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- -1 palmitoyl phospholipid Chemical class 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 claims description 2
- 108010030583 (melle-4)cyclosporin Proteins 0.000 claims description 2
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- KBARHGHBFILILC-NGIJKBHDSA-N N-[(7R,8R)-8-[(2S,5S,8R,11S,14S,17S,20S,23R,26S,29S,32S)-5-ethyl-1,7,8,10,16,20,23,25,28,31-decamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacont-2-yl]-8-hydroxy-7-methyloctyl]acetamide Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)CCCCCCNC(C)=O)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)N(C)C1=O)C(C)C KBARHGHBFILILC-NGIJKBHDSA-N 0.000 claims description 2
- 108010090287 SCY-635 Proteins 0.000 claims description 2
- 108010088573 STG-175 Proteins 0.000 claims description 2
- 108010058359 alisporivir Proteins 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 claims description 2
- 230000003592 biomimetic effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940066294 lung surfactant Drugs 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to the field of medicine, and in particular to anti-pneumonia drugs and their preparation methods and applications.
- nucleocapsid protein of the coronavirus SARS-CoV interacts with human cyclophilin A in the human body and plays an important role in virus maturation, virus replication and the formation of new virus particles.
- the invention provides an anti-pneumonia drug and its preparation method and application to facilitate the treatment of pneumonia diseases caused by coronavirus.
- the anti-pneumonia drug of the present invention includes a carrier loaded with an inhibitor; wherein the inhibitor is an inhibitor capable of blocking the binding of N protein and cyclophilin A; the carrier is pulmonary surfactant
- the bionic particles can treat pneumonia caused by coronavirus by blocking the combination of N protein and cyclophilin A.
- the mass of the carrier is 10-20 times the mass of the inhibitor.
- the bionic particles of pulmonary surfactant include phospholipid components of pulmonary surfactant, simulated components of proteins contained in pulmonary surfactant, and cholesterol components.
- the mass of the phospholipid component of the pulmonary surfactant is 10-20 times the mass of the cholesterol component.
- the protein-mimicking component contained in the pulmonary surfactant has the same content as the cholesterol component.
- the phospholipid component of the pulmonary surfactant is at least one of palmitchophospholipid and dipalmitoylphosphatidylglycerol.
- the simulated component of the protein contained in the pulmonary surfactant is dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000.
- the inhibitor is at least one of Debio-025, Cyclosporin A, NIM811, SCY-635, STG-175, MM284 and CPI-431-32.
- the average particle size of the carrier is 130-140 nanometers, and the dispersion index is less than 0.2.
- the preparation method of the anti-pneumonia drug of the present invention includes:
- S0 Provides inhibitors that can block the binding of N protein and cyclophilin A, palmitoyl phospholipid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and cholesterol;
- S1 Disperse the palm choline, the dipalmitoylphosphatidylglycerol, the dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and the cholesterol in an organic solvent, and then add the An inhibitor that blocks the binding of N protein and cyclophilin A is obtained to obtain a suspension containing drug-loaded particles, and the organic solvent is a good solvent for the inhibitor that can block the binding of N protein and cyclophilin A;
- S2 Perform a liposome extrusion process on the suspension containing drug-loaded particles at 40-60 degrees Celsius to obtain a carrier loaded with the inhibitor capable of blocking the binding of N protein and cyclophilin A.
- the palm choline, the dipalmitoylphosphatidylglycerol, the dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and the cholesterol are dispersed in an organic solvent.
- the steps include:
- dipalmitoylphosphatidylglycerol the dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and the cholesterol have the same quality.
- the anti-pneumonia drug of the present invention is used in the treatment of anti-SARS-CoV-2.
- the anti-pneumonia drug of the present invention is administered through the nasal cavity, oral administration or injection.
- Figure 1 is an imaging photograph of the lung organs of mice in vivo and in vitro according to an embodiment of the present invention
- Figure 2 is a photo of immunofluorescence staining of mouse lung tissue according to an embodiment of the present invention.
- the embodiments of the present invention provide an anti-pneumonia drug and its preparation method and application to facilitate the treatment of pneumonia caused by coronavirus.
- Embodiment 1 provides a method for preparing an anti-pneumonia drug, including:
- S0 Provides inhibitors that can block the binding of N protein and cyclophilin A, palmitoyl phospholipid, dipalmitoylphosphatidylglycerol, dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and cholesterol;
- S1 Disperse the palm choline, the dipalmitoylphosphatidylglycerol, the dipalmitoylphosphatidylethanolamine-methoxypolyethylene glycol 2000 and the cholesterol in an organic solvent, and then add the An inhibitor that blocks the binding of N protein and cyclophilin A is obtained to obtain a suspension containing drug-loaded particles, and the organic solvent is a good solvent for the inhibitor that can block the binding of N protein and cyclophilin A;
- S2 Perform a liposome extrusion process on the suspension containing drug-loaded particles at 40-60 degrees Celsius to obtain a carrier loaded with the inhibitor capable of blocking the binding of N protein and cyclophilin A.
- the inhibitor that can block the binding between N protein and cyclophilin A is cyclosporine polypeptide A.
- the step S1 of this embodiment is specifically:
- the temperature of the drug-loaded suspension is controlled to 50 degrees Celsius, and the drug-loaded suspension is sequentially passed through a 400 nanometer polycarbonate filter membrane and a 200 nanometer polycarbonate filter membrane to perform a liposome extrusion process to obtain cyclosporine polypeptide A-loaded Nanoparticles (abbreviated as P-CsA).
- P-CsA cyclosporine polypeptide A-loaded Nanoparticles
- the particle size and zeta potential of three groups of P-CsA were measured by Zetasizer, and the average particle size was 135.6 ⁇ 3.8 nanometers, the dispersion index was 0.148 ⁇ 0.056, and the zeta potential was 0.258 ⁇ 0.736mV.
- Example 2 provides the application of P-CsA of Example 1 in anti-SARS-CoV-2 treatment, specifically:
- CsA was administered intranasally to mice. After 24 hours, the near-infrared zone was used to image the living and isolated lung organs of the mice respectively.
- immunofluorescence staining analysis was performed on the lung tissues of the mice, and the results shown in Figure 1 were obtained. The imaging photos of mouse lung organs in vivo and in vitro are shown, as well as the immunofluorescence staining photos of mouse lung tissue shown in Figure 2. As can be seen from Figures 1 and 2, P-CsA can reach the lungs quickly and efficiently.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un médicament anti-pneumonie, son procédé de préparation et son utilisation. Le médicament anti-pneumonie selon la présente invention comprend un support chargé avec un inhibiteur. L'inhibiteur est un inhibiteur capable de bloquer la liaison de la protéine N et de la cyclophiline A ; le support est une particule bionique d'un tensio-actif pulmonaire, et peut bloquer la liaison de la protéine N et de la cyclophiline A pour traiter les pneumonies provoquées par des coronavirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/115234 WO2024040593A1 (fr) | 2022-08-26 | 2022-08-26 | Médicament anti-pneumonie, son procédé de préparation et son utilisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/115234 WO2024040593A1 (fr) | 2022-08-26 | 2022-08-26 | Médicament anti-pneumonie, son procédé de préparation et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024040593A1 true WO2024040593A1 (fr) | 2024-02-29 |
Family
ID=90012200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/115234 WO2024040593A1 (fr) | 2022-08-26 | 2022-08-26 | Médicament anti-pneumonie, son procédé de préparation et son utilisation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024040593A1 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053660A (zh) * | 2006-04-13 | 2007-10-17 | 复旦大学 | 一种蛋白多肽类药物载体及其制备方法和应用 |
| US20160082074A1 (en) * | 2014-03-11 | 2016-03-24 | Ludwig-Maximilians-Universitaet Muenchen | Compositions and methods for treating coronavirus infection |
| CN111074572A (zh) * | 2019-12-27 | 2020-04-28 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种抗呼吸系统病毒性疾病纤维的制备方法 |
| CN112472791A (zh) * | 2020-11-16 | 2021-03-12 | 复旦大学 | CsA脂质体在制备抗SARS-CoV-2药物中的应用 |
| CN113663073A (zh) * | 2021-08-19 | 2021-11-19 | 山东大学 | 一种靶向s蛋白棕榈酰化的多肽在制备广谱抗冠状病毒药物中的应用 |
-
2022
- 2022-08-26 WO PCT/CN2022/115234 patent/WO2024040593A1/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053660A (zh) * | 2006-04-13 | 2007-10-17 | 复旦大学 | 一种蛋白多肽类药物载体及其制备方法和应用 |
| US20160082074A1 (en) * | 2014-03-11 | 2016-03-24 | Ludwig-Maximilians-Universitaet Muenchen | Compositions and methods for treating coronavirus infection |
| CN111074572A (zh) * | 2019-12-27 | 2020-04-28 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种抗呼吸系统病毒性疾病纤维的制备方法 |
| CN112472791A (zh) * | 2020-11-16 | 2021-03-12 | 复旦大学 | CsA脂质体在制备抗SARS-CoV-2药物中的应用 |
| CN113663073A (zh) * | 2021-08-19 | 2021-11-19 | 山东大学 | 一种靶向s蛋白棕榈酰化的多肽在制备广谱抗冠状病毒药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0055041B1 (fr) | Composition pour la guérison de maladies du système respiratoire | |
| Stratmann et al. | Isoflurane differentially affects neurogenesis and long-term neurocognitive function in 60-day-old and 7-day-old rats | |
| JP4990929B2 (ja) | 肺臓内領域における活性成分のキャリヤーとしての半フッ素化アルカンの吸入及び点滴注入による使用 | |
| Zhao et al. | Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy | |
| JP5490683B2 (ja) | 肺サーファクタントの投与方法 | |
| WO2010083778A1 (fr) | Composition pharmaceutique injectable de liposome ciblant les poumons | |
| Tonnis et al. | A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals | |
| CN110461351A (zh) | 用tlr2激动剂治疗呼吸道感染 | |
| Fattal et al. | Lung toxicity of biodegradable nanoparticles | |
| AU2021253889A1 (en) | Compositions comprising nanoparticles, method of making and uses thereof | |
| JP2020502242A (ja) | 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物 | |
| WO2024040593A1 (fr) | Médicament anti-pneumonie, son procédé de préparation et son utilisation | |
| JP2023519958A (ja) | ウイルス及び細菌誘導性呼吸器疾患の治療のための拡散増強化合物の使用 | |
| JP2008266179A (ja) | 経肺用組成物 | |
| Kaipel et al. | Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs | |
| JP7475065B2 (ja) | 薬剤、肺胞の洗浄用の薬液、及び、ネブライザー | |
| JP2003530356A (ja) | 急性肺疾患の予防又は早期治療のための肺表面活性物質の新規使用 | |
| CN112472791A (zh) | CsA脂质体在制备抗SARS-CoV-2药物中的应用 | |
| US20200101019A1 (en) | Use of liposomes for treatment of chronic viral hepatitis b | |
| Scherließ et al. | Novel formulation concept for particulate uptake of vaccines via the nasal associated lymphoid tissue | |
| JPH10245346A (ja) | リポソーマル人カルシトニン遺伝子関係ペプチド組成物及びその製造方法 | |
| JP2003012543A (ja) | 糖尿病患者における空腹時血糖及び体重増加を減少させる方法又は医薬組成物 | |
| Wang et al. | Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy | |
| CN116549667B (zh) | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 | |
| EP4085932A1 (fr) | Arn modifié et stabilisé utilisé dans le traitement d'une maladie associée au gène du régulateur de la conductance transmembranaire de la mucoviscidose (cftr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22956138 Country of ref document: EP Kind code of ref document: A1 |